Crossmark Global Holdings Inc. Sells 3,484 Shares of Haemonetics Co. (NYSE:HAE)

Crossmark Global Holdings Inc. cut its holdings in shares of Haemonetics Co. (NYSE:HAE) by 34.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 6,514 shares of the medical instruments supplier’s stock after selling 3,484 shares during the period. Crossmark Global Holdings Inc.’s holdings in Haemonetics were worth $524,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HAE. Quarry LP bought a new stake in Haemonetics during the second quarter worth about $39,000. Covestor Ltd increased its position in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 438 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in shares of Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board acquired a new stake in shares of Haemonetics in the 2nd quarter valued at approximately $83,000. Finally, EntryPoint Capital LLC bought a new position in shares of Haemonetics in the first quarter valued at $86,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Stock Down 1.7 %

HAE stock opened at $89.22 on Friday. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The stock has a market capitalization of $4.48 billion, a price-to-earnings ratio of 37.02, a PEG ratio of 1.43 and a beta of 0.32. The business’s fifty day moving average price is $77.55 and its two-hundred day moving average price is $82.75.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the firm earned $0.99 earnings per share. On average, equities analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on HAE. Citigroup cut their price target on shares of Haemonetics from $94.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, August 22nd. Barrington Research reiterated an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a report on Friday, November 8th. CL King started coverage on Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price objective on the stock. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They set a “buy” rating and a $112.00 target price for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research note on Friday. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.